Nonalcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention group: consumption of one capsule per day (containing 300 mg hydroethanolic extract of purslane) for 12 weeks. Intervention 2: Control group: consumption of one placebo ca
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Being volunteer or Wishing to attend Age 18 years or older Alanine aminotransferase (ALT) greater than 19 IU/L for women and greater than 30 IU/L for men Evidence of fatty liver in ultrasonography with a score of 1 or more BMI: 20-40 kg/m2
Exclusion criteria
Exclusion criteria: Other acute or chronic hepatic disorders (hepatitis B or C) Biliary diseases Cancer Hypertension History of cardiovascular disease Nephrolithiasis (oxalate stones) or history of oxalate stones Consumption of omega-3 and vitamin E supplement Alcohol use Use of hepatotoxic medications during last month Changing medication dosage during the study Pregnancy Lactation Compliacne less than 80%
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alanine aminotransferase (ALT). Timepoint: At the begining and at the end of week 12. Method of measurement: Laboratory kit.;Aspartate aminotransferase (AST). Timepoint: At the begining and at the end of week 12. Method of measurement: Laboratory kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Weight. Timepoint: At the begining and at the end of week 12. Method of measurement: Seca scale.;Body mass index (BMI). Timepoint: At the begining and at the end of week 12. Method of measurement: Calculation: weight (in kilograms) divided by the square of height (in meters).;Waist circumference. Timepoint: At the beginning and at the end of week 12. Method of measurement: Non-stretchable measuring tape.;Liver steatosis. Timepoint: At the beginning and at the end of week 12. Method of measurement: Sonography.;Systolic blood pressure (SBP). Timepoint: At the beginning and at the end of week 12. Method of measurement: Sphygmomanometer.;Diastolic blood pressure (DBP). Timepoint: At the beginning and at the end of week 12. Method of measurement: Sphygmomanometer.;Total cholesterol. Timepoint: At the beginning and at the end of week 12. Method of measurement: Laboratory kit.;Triglyceride (TG). Timepoint: At the beginning and at the end of week 12. Method of measurement: Laboratory kit.;High density lipoprotein (HDL). Timepoint: At the beginning and at the end of week 12. Method of measurement: Laboratory kit.;Low density lipoprotein (LDL). Timepoint: At the beginning and at the end of week 12. Method of measurement: Laboratory kit.;Albumin (ALB). Timepoint: At the beginning and at the end of week 12. Method of measurement: Laboratory kit.;Alkaline phosphatase (ALP). Timepoint: At the beginning and at the end of week 12. Method of measurement: Laboratory kit.;Gamma glutamyl transferase (GGT). Timepoint: At the begining and at the end of week 12. Method of measurement: Laboratory kit.;Total bilirubin. Timepoint: At the beginning and at the end of week 12. Method of measurement: Laboratory kit.;Fasting blood sugar (FBS). Timepoint: At the beginning and at the end of week 12. Method of measurement: Laboratory kit.;Insulin. Timepoint: At the beginning and at the end of week 12. Method of measurement: Laboratory kit (ELISA).;Homeostatic model assessment of insulin resistance ( | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Farzad Shidfar
Iran University of Medical Sciences
Outcome results
None listed